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Summary 
The accumulating evidence in favor of tumor immunosurveillance indicates that immunotherapies may prove 
effective for the treatment of cancer. Many current approaches against cancer immunotherapy are often limited in 
their potential to induce effective anti-tumor immune responses. However, recent approach with dendritic cell 
based therapy proves to be an effective method for induction of anti-tumor immune response. In this review we 
discuss the effectiveness and complications associated with DC based immunotherapy and new strategies being 
perused for effective anti cancer response. 
 
 
I. Introduction 
Immunotherapy offers an attractive alternative and 
also a potential combination therapy to augment 
conventional chemotherapy and radiotherapy. It aims to 
exploit body’s natural anti-tumor defenses by stimulating 
immunity and thus leading to tumor regression. Using the 
body’s own protective mechanisms is attractive for a 
number of reasons, including low toxicity, a high degree 
of specificity, and the avoidance of cytotoxic drugs. 
Immunotherapy is generally thought of as conferring 
either passive or active immunity. Passive immunity 
involves direct injection of the host with – antibodies, 
cytotoxic T cells etc. without the involvement of host 
immune response. Antibody based approaches were the 
first form of passive immunotherapy to reach fruition as 
accepted cancer therapies. Monoclonal antibodies such as 
anti-HER2 (Herceptin) and anti-CD20 (Rituxan), 
represents some of them in therapeutics (Riethmuller et al, 
1993; Weiner et al, 2000). However, there are 
considerable evidences that suggest that cancer patients 
have T cells that are capable of attacking tumor (Urban et 
al, 1992; Boon et al, 1994; Kawakami et al, 1997). This 
has led to the suggestion that isolating the tumor 
infiltrating T lymphocytes or whole T cells, activating 
them in vitro with IL-2, a potent T cell growth factor and 
reintroduce them into the patients. These approaches have 
met with some success, albeit short-lived. The expanding 
research in T cell biology given us broad view of 
understanding that the infused tumor infiltrating T cells 
are the mix of all CD4+ and CD8+T Subsets, including 
Tregs and Th2 cells. Reinfusing the expanded whole T 
cells together with these Tregs and Th2 may limit the anti- 
tumor function by their secreted tumor promoting factors. 
However, infusion of antibody or T cells without the 
involvement of host-immune system has a shorter half-life 
in situ, resulting in diminished anti-tumor immunity.  
Other methods besides passive immunization, such 
as active immunity where host immune system is directly 
involved in inducing anti-tumor response have been 
proposed as ideal therapy for long term efficacy. Active 
immunity is an endogenous immune response, where the 
immune system is primed to recognize the antigen/tumor 
for induction of anti-tumor response. Such therapies offer 
a unique mechanism of tumor recognition based on the 
ability of the T cell to distinguish single amino acid 
differences in any mutated cell protein (tumor specific 
antigens, TSA) or self antigens (tumor associated antigen, 
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TAA). The self antigens may differ in density of antigen 
expression from any compartment of the cell (Urban et al, 
1992). Many tumors induce immune tolerance, and the 
reason for induction of such tolerance is the inefficient 
presentation of tumor antigen(s) to the immune system. To 
induce an immune response to tumor antigens the T cells 
must receive instruction to recognize tumor antigen(s) on 
tumor cells. Effective antigen presentation requires HLA 
molecules, but also co-stimulatory molecules, cytokines 
and chemokines needed for priming naïve T cells. The 
unique combination of these membranes bound and 
secreted molecules are characteristic of APCs, of which 
dendritic cells are the potent one. Many factors appear to 
be responsible for the unique potency of DCs in activating 
T cells. These cells express 50-100 fold higher levels of 
MHC molecules than macrophages, providing more 
peptide/MHC ligand for T cell receptor engagement. Also, 
they express extremely high levels of important adhesion 
and costimulatory molecules critical for T cell activation 
(Banchereau and Steinman, 1998). Other DC specific 
genes, such as one encoding a T cell specific chemokine 
DC-CK1 (Adema et al, 1997), add to the list of features 
that give DCs their unique prowess in initiating T cell 
response and boost secondary immune response to foreign 
antigens. Because of these properties, much attention has 
been directed toward the use of DCs in vaccine strategies 
for the treatment of cancer. 
 
A. Dendritic cells in immunity to tumors 
Dendritic cells are professional antigen presenting 
cells and are the most powerful stimulators of naïve T 
cells (Banchereau et al, 2000; Liu et al, 2001). In the in 
vivo scenario of tumor bearing animals or cancer patients, 
the dendritic cells that have phagocytosed tumor cell 
debris process the material for MHC presentation, 
upregulate expression of costimulatory molecules and 
migrate to regional lymph nodes to stimulate tumor 
specific lymphocytes. This pathway produces CD4+ and 
CD8+ Tcells that react with the MHC restricted tumor 
peptides that are derived from mutated proteins, aberrantly 
expressed gene products and normal differentiated 
antigens that are produced by the tumor cells. CD4+ T cells 
can also provide help for the production of antibody 
responses against tumor associated gene products (Figure 
1). There is also evidence that infiltration of tumor with 
dendritic cells has been associated with a better prognosis 
in different types of malignancies (Hillenbrand et al, 1999; 
Poindexter et al, 2004; Sandal et al, 2005). 
Collectively all these findings show that cancer 
bearing hosts can frequently mount anti-tumor immune 
response. However, subsequent progress and development 
of clinical grade tumors also indicate that the initial 
immune responses initiated by DC are not enough to 
preclude disease progression and tumor cells are capable
 
 
 
Figure 1. DC play a central role in the elicitation and maintenance of anti-tumor immune response. DC acquire, process and present 
tumor-associated or tumor-specific antigens and present the epitopes to both CD4+ and CD8+ T cells. The CD8+ T cells exert IFN-?-
dependent and independent anti-tumor cytotoxic activity. The CD4+ T cells help B cells to form antibody and also secrete inflammatory 
cytokines that cause inflammation into the tumor tissue. 
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of evading host immune-responses. Studies have indicated 
that tumors can evade immune responses by effecting DC 
biology at different stages of their development, 
maturation and function (Figure 2). Gabrilovich and 
colleagues, 1996 reported ineffective CTL induction in a 
murine mutant p53 fibrosarcoma model associated with 
defects in DC function. Supernatants from tumor cells 
suppressed DC maturation, ultimately attributed to an 
effect of VEGF (Gabrilovich et al, 1996). Inhibition of the 
differentiation of dendritic cells from CD34+ progenitors 
by tumor cells: role of IL-6 and M-CSF (Menetrier-Caux 
et al, 1998). STAT-3 activation in tumor cells induces the 
elaboration of multiple factors that inhibit dendritic cell 
differentiation, one of which is VEGF (Gabrilovich et al, 
1996; Niu et al, 2002). Metastatic melanoma secreted IL-
10 that down regulates CD1on dendritic cell in tumor 
lesions (Gerlini et al, 2004). Increased level of IL-10 in 
serum from patients with hepatocellular carcinoma 
correlate with profound numerical deficiencies and 
immature phenotype of circulating DC subsets 
(Beckebaum et al, 2004). Patients with squamous cell 
carcinoma of the Head and Neck show alterations in the 
frequency of dendritic cell subsets in the peripheral 
circulation (Hoffman et al, 2002). Dendritic cell function 
is also suppressed by cyclooxygenase-2 from tumors 
(Sharma et al, 2003). Decreased antigen presentation by 
dendritic cells in patients with breast cancer have been 
also reported (Gabrilovich et al, 1997). Tumor infiltrating 
dendritic cells have been reported to be defective in 
antigen presentation inducible expression of B7 (Chaux et 
al, 1997). 
 
B. Advantages of DC therapy 
DC have been cultured in vitro for treating cancer 
patients. A key advantage of differentiating dendritic cells 
in vitro is that the precursor-DC are removed from 
immunosuppressive tumor environment. Next advantage 
of DC culture in vitro is that the high endocytic capacity of 
DC can be exploited for efficient loading with antigen of 
choice, such as protein, peptide, tumor lysate etc 
(Mayordomo et al, 1995; Holtl et al, 2002; Shibagaki et al, 
2002). DC can also take up and express RNA (encoding 
tumor antigen) or with recent development in DNA 
transfer technology viral vectors can be reliably transfer 
transgene for intracellular expression (Boczkowski et al, 
1996; Jenne et al, 2001). The advantage of loading DCs in 
vitro using these approaches is the ability to concentrate 
often limited supplies of antigens into DC. It has also been 
reported that DC can be activated matured with different 
immuno-stimulatory microbial adjuvants such as CpG, 
LPS, etc prior to in vivo delivery for effective induction of 
anti cancer immune response (Atkins et al, 2003; Okamoto 
et al, 2003; Pulendran, 2004). 
 
C. Immunotherapeutic potential of 
dendritic cells 
To date DC based therapy has produced promising 
results in both basic research and clinical trials. DC 
generated in vitro from bone marrow progenitor’s 
stimulated allogenic T cell response. DCs pulsed with 
tumor lysate, tumor protein extracts, and synthetic peptide 
tumor epitopes or DCs fused with irradiated tumor cells 
could generate protective immunity to subsequent tumor 
challenge in animal models. 
A number of DC cancer vaccine trials have been 
reported so far. Hsu and colleagues, 1996 reported the first 
DC vaccine trial for the treatment of cancer in patients 
with follicular B cell lymphomas. Using tumor specific
 
 
Figure 2. Tumors can evade the host immune response from dendritic cell mediated initial stage of immune recognition and activation 
by their secreted suppressive factors. To evade host immunity tumors use several strategies to hinder normal DC differentiation, 
maturation and function. For example, the tumor associated cytokines IL-6, M-CSF, IL-10, VEGF, TGF-? and COX-2 
(Cyclooxygenase-2) inhibit DC differentiation, maturation and function, preventing activation of potentially protective anti-tumor 
immunity. 
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idiotype immunoglobulin pulsed DCs in patients with 
follicular lymphoma, Timmerman and colleagues, 2002, 
reported 2 long–lasting complete responses (CRs) and 1 
partial response (PR) among 10 patients with measurable 
disease in the pilot phase of study. Next to lymphoma, 
clinical trial reports made a considerable success in 
patients with multiple myeloma. Clinical trials of peptide 
loaded DCs have been reported in patients with cancer, 
including melanoma, with encouraging immune response, 
and possible clinical responses detected. Patients with 
advanced breast and ovarian cancer have been treated with 
DCs loaded with peptide from HER-2/neu or MUC1 
peptide specific IFN-? producing CTL were detected in 5 
of 10 patients. Holtl and colleagues, 2002 reported a trial 
of 35 patients with metastatic renal cell carcinoma who 
received monthly injections of autologous, mature 
monocyte derived DCs loaded with tumor lysates. Of 27 
evaluable patients, 2 had objective CR, 1 had PR, and 7 
had stable disease. Objective responses and and disease 
stabilization were long lasting, ranging from 6 months to 3 
years. Yu and colleagues, 2001 reported first time a trial of 
10 patients with malignant glioma who received three 
injections 2 weeks apart with autologous DCs pulsed with 
tumor lysates. Six of 10 patients demonstrated robust 
systemic cytotoxicity as demonstrated by IFN-? expression 
by peripheral blood mononuclear cells in response to 
tumor lysate after vaccination. Using HLA-restricted 
tetramer staining, they identified a significant expansion in 
CD8+ antigen-specific T-cell clones against one or more of 
tumor-associated antigens MAGE-1, gp100, and HER-2 
after DC vaccination in four of nine patients. The median 
survival for patients with recurrent glioblastoma 
multiforme in this study (n = 8) was 133 weeks. In another 
study Heiser and colleagues, 2002 reported the efficacy of 
autologous dendritic cells transfected with RNA encoding 
prostate specific antigen stimulate CTL responses against 
metastatic prostate tumors. In 13 study subjects, escalating 
doses of PSA mRNA-transfected DCs were administered 
with no evidence of dose-limiting toxicity or adverse 
effects, including autoimmunity. Induction of PSA-
specific T cell responses was consistently detected in all 
patients, suggesting in vivo bioactivity of the vaccine. 
Vaccination was further associated with a significant 
decrease in the log slope PSA in six of seven subjects; 
three patients that could be analyzed exhibited a transient 
molecular clearance of circulating tumor cells. Maier 
colleagues, 2003 reported the vaccination of patients with 
cutaneous T cell lymphoma by monocytes derived 
dendritic cells. The patients were treated with intranodal 
injection dendritic cells pulsed with tumor lysate protein 
and keyhole limpet hemocyanin (KLH). Tumor specific 
delayed-type hypersensitivity (DTH) reactions developed 
in 8 of 8 patients challenged with tumor-lysate pulsed DCs 
and in 3 of 8 patients challenged with tumor lysate alone. 
Three of 5 patients showed significant tumor-lysate 
specific increase of in vitro peripheral blood lymphocyte 
proliferation coinciding with increased interferon-alpha 
(IFN-?) production. Five of 10 (50%) patients had 
objective responses. Four patients had partial responses 
(PRs). One patient had a complete response (CR) for 19 
months that is ongoing. The remaining 5 patients had 
progressive disease. In the 5 responder patients, 6.8 +/-1.4 
vaccinations were necessary to induce an objective clinical 
response. Response was associated with low tumor 
burden. A peptide based DC vaccine was used by Svane 
and colleagues, 2004, who demonstrated how wild type 
p53 derived HLA-A2 binding peptides are able to activate 
human T cells in patients with advanced breast cancer. In 
this phase I pilot study, the toxicity and efficacy of 
autologous dendritic cells loaded with a cocktail of three 
wild-type and three modified p53 peptides are analyzed in 
six HLA-A2+ patients with advanced breast cancer. 
Vaccinations were well tolerated and no toxicity was 
observed. Disease stabilization was seen in two of six 
patients, one patient had a transient regression of a single 
lymph node and one had a mixed response. ELISpot 
analysis showed that the p53-peptide loaded DCs were 
able to induce specific T cell responses against modified 
and unmodified p53 peptides in three patients. 
 
D. Promises and pitfalls 
A central goal of immunotherapy is to activate tumor 
antigen specific Tcells. To enhance T cell responses to 
tumors, DCs have been investigated for their ability to 
prime CD4+ and CD8+T cells. Established techniques for 
growing DCs in culture ex vivo have allowed development 
of DC based vaccines. In light of promising preclinical 
results, clinical trials for many tumor types have been 
initiated using ex vivo generated DC vaccines. Although 
these trials showed overall that immune responses could 
be generated against tumor antigens, but limited success 
have been achieved by using these protocols (Ridgway, 
2003). These results underscore the potentials for 
improvement of DC based immunotherapy for cancer 
prevention. Similarly, different improved vaccination 
strategies can be adopted for increasing efficiency of DC 
vaccination. 
 
E. DC generation 
Currently the major sources of human DC for 
immunotherapy are (1) blood derived DC obtained 
through a modified gradient method (Zhang et al, 2002). 
The use of DC directly from the peripheral blood is 
complicated by the low percentage of them in blood. The 
most frequently described method for obtaining DCs 
remain ex vivo generation from peripheral blood 
precursors such as (2) generation from CD34+ progenitor 
cells using complex cytokine cocktails including SCF, IL-
3, IL-6, GM-CSF, TNF-? and IL-4 (Palucka et al, 2003; 
Di Nicola et al, 2004; Paczesny et al; 2004). (3) 
Differentiating DCs from leukapheresis derived 
monocytes with GM-CSF and IL-4 (Thurner et al, 1999). 
All three types of DC preparation can stimulate antigen- 
specific T cell responses in human subjects and have been 
associated with clinical responses in cancer patients. No 
direct comparisons between different methods of DC 
generation and vaccination efficiency have been 
performed in clinical trials yet.  
However, these methods of DC generation in vitro 
are time-consuming and laced with different regulatory 
concerns. Recently, to overcome these limitations of in 
vitro DC generation, attempts have been made to generate 
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DC in vivo by using various cytokines and their 
combination. Prominent among them are the use of FLT-3 
ligand (Fong et al, 2000, 2001; Marroquin et al, 2002) 
GM-CSF and IL-4 (Roth et al, 2000), etc. Various animal 
model studies of in vivo DC generation and tumor 
immunotherapy has indicated that transient anti tumor 
response can be induced in such models (Chen et al, 1997; 
Lynch et al, 1997; Basak et al, 2002; Bjorck et al, 2002). 
Some of these studies are undergoing clinical trials in 
cancer patients for various diseases. These studies have 
opened up a new frontier in vivo DC mediated 
immunotherapy not only for cancer immunotherapy but 
also for various diseases. However, these studies need 
further evaluation for subset of DC induction by such 
method, strategies for effective in vivo antigen loading etc. 
 
F. Choice of DC for immunotherapy 
The different methods of DC generation result in 
different types of DC both in vitro as well as in vivo that 
differ in their markers and functions (Liu et al, 2001). 
Choosing the ideal DC for use in therapeutic purpose has 
been complicated by the diversity of DC and moreover, it 
will be critical to consider the function of distinct DC 
subsets, and induction of appropriate maturation and 
migration. If the antigen is loaded onto a different DC 
subset and/or fails to induce its maturation, the DC may 
not induce protective immunity, and possibly it may cause 
the induction of tolerance (Steinman et al, 2003). Humans 
DC subsets can be broadly subdivided into two distinct 
types of DC subsets that are identified in vivo on the basis 
of their ability for cytokine production, surface marker 
expression and induction of T cell response (Banchereau 
et al, 2000; Steinman, 2003). The subsets include the 
traditionally described myeloid–derived DC1 and the more 
recent described plasmacytoid-DC2 (Figure 3). Recently, 
considerable interest has been directed toward identifying 
the type of T cell response induced by these different DC 
subsets. The tolerogenic role of DCs could compromise 
vaccine efficacy. One mechanism contributing to 
immunologic unresponsiveness toward tumors may be 
presentation of tumor antigens by tolerogenic host DCs. 
Studies in mice and humans have shown that tolerogenic 
DC exerts its suppressive activity in many ways.In 
humans, a subset of monocyte derived DCs has been 
described that expresses indoleamine 2, 3 dioxygenase 
(IDO), inhibits T cell proliferation, and induces T cell 
death. IDO mediated suppressor activity was found in 
fully mature as well as immature DCs. Large number of 
IDO-DCs can be found in tumor draining lymph nodes, 
suggesting that they may be involved in immunologic 
unresponsiveness seen in cancer patients (Munnet al, 
2002). DC STAT3 actively may be critical to the induction 
of antigen specific T cell tolerance. Stat3 is activated by 
tyrosine phosphorylation following DC exposure to IL-10 
and other factors produced by tumor cells, and forced
 
Figure 3. The family of Human DC displays considerable heterogeneity .DC may derive from two potential lineages: myeloid and 
lymphoid. Myeloid progenitors give rise to two main precursors, CD14- D11C+ precursors and CD14+ CD11C+ precursors. CD14+ 
CD11C+ cells differentiate in the presence of GM-CSF and IL-4 into interstitial DC, which corresponds to dermal DCs in vivo. CD14- 
CD11C+ precursors yield DC of Langerhans cell type in response to GM-CSF and IL-4. The second major subset of DC with a presumed 
lymphoid origin is CD14- CD11C+ IL-3R+ DC precursor called PDC2, plasmacytoid T cells. These cells depend on IL-3 as survival 
factor. 
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expression of activated Stat3 in DCs can result in impaired 
antigen specific T cell responses (Nefedova et al, 2004; 
2005). 
DC1 subsets polarize T-cells toward the Th1 
functions and DC2 polarize DC toward Th2 functions. It 
has been also reported that DC1 induces the differentiation 
of naïve CD8+ T cells into CTL whereas DC2 induces a 
population of CD8+ T regulatory cells that are anergic, 
non-cytolytic and capable of inhibiting primary T cell 
responses through the production of IL-10 (Gilliet et al, 
2002). DC2 are also responsible for IFN-? production 
when stimulated with pathogens and ligands for toll 
receptors (Colonna et al, 2004).  
Thus, it may be more appropriate to choose the 
source of DC by the type of T cell response desired for 
anti-tumor responses, that is mostly Th1 type of immune 
response for effective cancer immunotherapy. There is a 
need to determine optimal conditions for expansion of DC 
that specifically promote anti-tumor T cell response and to 
devise methods for selectively removing undesirable DC 
subsets for effective cancer immunotherapy. 
 
G. Approaches for antigen preparation 
and DC loading 
The optimal strategy for tumor antigen delivery to 
DCs remains one of the important aspects that clearly 
deserves further exploration. Antigen can be delivered to 
DCs in the form of MHC restricted peptides, protein, 
tumor derived antigen mixtures or through transfection 
with genetic materials, each of which greatly influence the 
efficacy of T cell activation by dendritic cells (Figure 4). 
Ample evidences indicate that CD4+T cells, particularly 
IFN-? producing Th1 cells are another critical component 
of an effective anti tumor immune response as Th1 (1) 
help to initiate antigen specific CD8+T cells by expressing 
CD40L and activating DCs via CD40 (Bennett et al, 
1998). (2), that amplifies and sustain CD8+ T cell function 
by secreting cytokines such as IL-2 (Hung et al, 1998). (3). 
Help in the formation and retaining memory CD8+ T cells 
(Shedlock et al, 2003; Sun et al, 2003) Thus, a DC vaccine 
should incorporate antigens targeting both CD4+nd CD8+ 
T cells. 
 
H. Peptides and proteins 
Several approaches have been developed to arm DCs 
with tumor antigen for use in experimental animal model 
and clinical trials. The most widely used being incubation 
of DCs with MHC restricted peptides; which can directly 
bind to MHC molecules on cell surface. A broad array of 
tumor specific peptides presented by different HLA class I 
and class II molecules recognized by CD8+ and CD4+ T 
cells had been identified. These defined tumor peptides 
can be readily synthesized and used to load onto ex-vivo 
generated DCs. Vaccination with peptide pulsed DCs has 
been shown to induce both peptide specific CD8+ and 
CD4+ Tcells in healthy volunteers and even in advanced 
cancer patients (Mayordomo et al, 1995; Celluzzi et al, 
1996; Schuler-Thurner et al, 2002). Although 
straightforward and technically easy, peptide based 
approach has some major limitations. The choice of 
peptides is restricted to the HLA typing of the patient, at 
least for HLA class I peptides, which are less promiscuous 
binders than HLA class II peptides. Vaccination with 
peptide pulsed DCs should only induce a T cell response 
directed against a limited number of tumor antigens, which 
may not be sufficient to effectively combat the tumor. In 
this scenario, the tumor might escape the immune response 
directed against a small array of peptides and emergence 
of antigen-loss tumor cell variants may occur. Using MHC 
I–restricted peptides ignores the role of MHC-II-restricted 
T helper cells in initiating and sustaining an immune 
response. DCs loaded with a mixture of peptides may 
induce responses only to immunodominant T cell epitopes,
 
 
 
 
Figure 4. To date, several approaches have been used to load DCs with tumor antigens for use in clinical trials. DC may be loaded with 
peptide, recombinant protein or purified proteins, tumor lysates. It can also be transfected with RNA, plasmid vector encoding tumor 
antigens, or transduced with non-replicating recombinant viral vectors. 
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than compromising the ability to mount a broad T cell 
immune response that limit the risk of tumor strategies to 
elicit simultaneous CD4+ and CD8+ T cell response. Use of 
longer peptides provided that they contain both class1 and 
class II epitopes could be useful. Recent report by Millard 
and colleagues, 2003 suggested that DC KLH loading 
together with MHC I peptide induced a strong cytotoxic T 
lymphocyte response against the peptide. Such a 
concomitant presentation of KLH and peptide by the same 
DC strongly augmented the peptide specific CTL 
response, as compared to the response induced by DC 
pulsed with the peptide alone. The use of optimized 
peptide and KLH loaded DC may improve the efficacy of 
therapeutic anti-tumor peptide vaccination. Although DCs 
can be loaded with peptides, the half-life such peptide 
MHC complex is relatively short. Substitution of favorable 
key peptide residues enhances affinity of MHC-Peptides 
or stability of the T cell receptor of a T cell specific for 
MHC-Peptide complexes, and this enhancement has 
correlated with improved T cell responses and anti-tumor 
activity both in vivo and in vitro. In addition Wang and 
colleagues, 2002 demonstrated that TAT mediated 
delivery of T cell peptides into DC results in prolonged 
antigen presentation and enhanced T cell responses. These 
results suggest that TAT-mediated peptide delivery can 
enhance the efficacy of DC mediated cancer 
immunotherapy. 
Protein may offer some advantages over peptide 
antigen since they may contain more than one antigenic 
epitopes, including MHC class II T- helper epitope, and 
they may avoid the need for MHC restriction. Under 
normal circumstances, addition of intact soluble proteins 
to DC would be expected to result in entry of the proteins 
into MHC II processing pathway, which allow for 
presentation of antigenic epitopes to CD4+ T cells. 
Although DC may also present exogenous antigens on 
MHC I molecules, which can lead to the activation CD8+T 
cells, this occurs inefficiently. To overcome this problem 
there are number of approaches are being developed, 
including transferring gene that result in antigen 
processing in the MHC1 pathway of DC to activate CD8+T 
cells. Conjugating certain transporters peptides onto full-
length proteins allow these to translocate across cell 
membranes and into the MHC class I pathway. Targeting 
protein antigens to Fc receptors on DCs using antibody 
complexes has been shown to activate both CD4+ and 
CD8+ T lymphocytes in vivo and in vitro (Regnault et al, 
1999). Cross presentation can also be enhanced by 
targeting DC surface receptors such as DEC-205 (Mahnke 
et al, 2000). In addition the application of sterically 
stabilized liposomes encapsulated protein loading of DC 
offers a novel effective, safe vaccine approach if a 
combination of CD4+ and CD8+ T cell responses is desired 
(Ignatius et al, 2000). Several methods exist for production 
of proteins in large amount in vitro by cell culture 
techniques. However manufacturing of clinical grade 
proteins by GMP facilities are monitored by stringent 
regulatory procedures. 
 
I. DNA and RNA 
Loading DC with genetic material permits delivery 
of full-length antigens and has the advantage of easier 
manufacture than full-length protein. Although DC may be 
loaded with DNA, the efficiency of transfection is low and 
viral vectors are generally used to deliver DNA (Jenne et 
al, 2001). An alternative is to load DC with mRNA 
encoding tumor antigens or derived from tumor, either as 
naked genetic material or with liposomes or 
electroporation (Heiser et al, 2001; Muller et al, 2003; 
Nencioni et al, 2003). Although DCs can be loaded with 
mRNA, obtainable and amplifiable from small specimen 
of tumor, this may lead to autoimmune diseases. 
 
J. Viral vectors 
Several different types of viral vectors have been 
developed for delivering genes to DC. Recent strategies 
have focused on retroviruses, lentiviruses, and 
adenoviruses as the main viral vectors for antigen delivery 
to DC. Recent studies with retroviruses found that they 
can successfully transduce proliferating CD34+ progenitors 
prior to differentiation to DC (Jenne et al, 2001). 
Lentiviral vectors represent a possible advance over 
retroviruses because they can transduce dividing and 
nondividing cells with the efficiency of 90% moreover 
those transuded DCs maintained their characteristic 
phenotype and allostimulatory capacity (Chinnasamy et al, 
2000; Dyall et al, 2001; He et al, 2005). Adenoviral 
vectors have also shown to transfer genes to DC, and these 
now entering clinical trials due to greater and faster virus 
entry and to an increased transgene expression, especially 
following DC maturation with 100% potential, and no 
cytopathic effects on the infected DCs (Dietz et al, 1998). 
Pox virus vectors such as avipox and vaccinia are also 
suitable for transduction of DCs; however infection is 
followed by a significant decrease in viability of immature 
DCs, which undergoes apoptosis. Furthermore, infected 
immature DCs show a block in maturation, impairing their 
T cell stimulatory properties (Jenne et al, 2000). The major 
drawback in using virus infected DCs is the induction of 
antiviral cellular and humoral immune responses in 
patients, which may impair the desired induction of anti-
tumor response and the destruction of subsequently 
administered DCs. In this regard modified virus lacking 
viral genome components have been developed. To 
achieve these goals “gutless” adenoviral vectors lacking 
viral genome has been developed that may facilitate 
lowering of anti viral immune response (Basak et al, 2004; 
Harui et al, 2004). To overcome similar problems of viral 
vector based antigen deliver to DC, further basic research 
involving viral vectors and DC interaction needs to be 
evaluated.  
 
K. Tumor cell lysates 
To optimize the anti-tumor effects of DC based 
immunotherapy it is tempting to allow the DCs to present 
the whole antigenic spectrum of a given tumor. Tumor cell 
lysates are good source of whole tumor antigens (Strome 
et al, 2002). These tumor lysates can be loaded on DC 
effectively for induction of an anti-tumor T cell response 
directed against a broad array of tumor antigens. Thus the 
probability of tumor escaping by loss of antigen(s) can be 
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reduced. The use of tumor lysate as antigenic source has 
several advantages, which include mimicking the 
physiologic processes by which a growing tumor induces 
an immune response in vivo. Tumor lysates circumvent the 
need for molecular characterization of the tumor antigen(s) 
for effective immunization. The approach of using tumor 
lysates pulsed onto DC would offer the potential 
advantage augmenting a broader T cell immune response 
to tumor–associated antigens that would not be obtained 
by pulsing DC with a single or perhaps several defined 
tumor peptides. Several concerns have been raised 
regarding this approach. First, it is often difficult to obtain 
sufficient quantities of autologous tumor material from 
patients. The use of allogenic tumor cell lines may present 
an alternative to overcome this problem and even amplify 
the immune response by activation of alloreactive T cells. 
Second, immunizing with DCs loaded with whole tumor 
cell preparations bears the potential risk of inducing 
autoimmunity against self antigens expressed on tumor.  
 
L. DC-Tumor cell fusion 
Another approach for delivering the full complement 
of tumor antigens to DC is to produce fusions of tumor 
and DC .The concept behind this approach is to use 
autologous tumor cells with DCs, thereby allowing for the 
co expression of all relevant tumor antigens and DC 
molecules within the same cell. Preclinical data has 
demonstrated that DC fused with tumor cells are potent 
inducers of tumor specific immune responses (Wang et al, 
1998; Siders et al, 2003). A similar approach of fusing 
autologous tumor and allogenic dendritic cells has been 
used to vaccinate patients with advanced renal cell 
carcinoma, and this trial met with some success (Kugler et 
al, 2000, Kikuchi et al, 2001, 2004). DC may be fused 
with autologous, HLA matched, or unmatched tumor cells 
and appear to stimulate CTL activity in autologous T cells 
(Koido et al, 2001). One of the main limitations for the 
clinical use of an approach of this type, besides the need of 
primary tumor, is the efficiency with which fusions can be 
achieved between DCs and tumor cells in the absence of 
selection. 
 
M. Maturation of antigen-loaded DC 
The immunization of patients with antigen loaded 
immature DCs can result in tolerance or suppression of 
antigen specific response (Dhodapkar et al, 2001). This 
has led to the suggestion that DCs should be loaded with 
antigen in the presence of maturation signals or it can be 
transduced with genes that encode maturation signals. An 
important issue regarding ex vivo antigen loaded DC is the 
degree of maturation that is induced in vitro and its 
relevance to the homing and function of loaded DCs after 
re-injection. At present, the maturation protocols used for 
the DC therapy are quite variable and range from the use 
of monocyte conditioned medium to various defined 
agents, such as TNF-?, IL-1?, soluble CD40L and 
prostaglandins (Jonuleit et al, 1997; Reddy et al, 1997; 
Scandella et al, 2002). However, the processes leading to 
DC maturation, using PGE2 need further investigation. 
Because recent data suggest that PGE2 may be necessary 
to determine DC responsiveness to MIP3?, which attract 
them to the afferent lymph nodes from the injection site. 
This requirement apply to monocyte-derived DCs, 
whereas circulating CD1+DCs may not need this 
prostaglandin in order to migrate. In light of this evidence, 
addition of PGE2 to the culture medium before DC 
injection may help improve vaccination efficacy, 
especially when DCs are generated from monocytes. On 
the other hand PGE2 inhibits the secretion of IL-12 by 
DCs(Kalinski et al, 1998, Spisek et al, 2001), and induce 
regulatory T cells (Akasaki  et al, 2004, Sharma et al, 
2005, Baratelli et al, 2005) and is therefore likely to 
decrease the efficacy of Th1 priming in vivo. Hence so far, 
it is possible to construct arguments both for and against 
the inclusion of PGE2 in DC-based anticancer therapies on 
the basis of in vitro results, but extremely difficult to 
predict whether the presence of PGE2 during DC 
maturation will increase or decrease the efficacy of anti-
tumor therapy in vivo. In addition, dendritic cells can be 
activated and matured by some danger signals such as Uric 
acid (Shi et al, 2003), Bradykinin (Aliberti et al, 2003) and 
heat shock proteins (Binder et al, 2000; Manjili et al, 
2005). The important of using mature DC rather than 
immature DCs have a greater potential to migrate to the T 
cell areas of draining lymph nodes (De Vries et al, 2003). 
The sequence of antigen loading and maturation is also an 
important aspect of effective tumor antigen presentation 
(Figure 5). For example, if protein or messenger RNA is 
 
 
 
Figure 5. Maturation of DC in vitro. The current standard method of inducing DC maturation prior to injection is by adding cocktails of 
pro-inflammatory cytokines such as IL-1?, IL-6, TNF-?, and GM-CSF. In addition CD40L or TLR ligands such as CPG and LPS also 
can be used for inducing DC maturation. 
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used for loading DC, only the immature DC are good at 
antigen uptake and they should be matured after efficient 
loading. Contrary to this, if peptides are loaded, which 
requires no processing before antigen presentation by DC, 
the DC can be mature first and then load to optimize the 
number of MHC molecules on the surface. Life span of 
antigen bearing DCs in lymphoid organs/tissues may also 
be an important key for determining the outcome of 
protective T cell response, most likely by regulating the 
availability of antigen for these cells. Recent findings 
provide direct evidence that the survival genes such as 
Bcl2 and bcl-XL are required for the promotion of DC 
survival by TLR ligands and T cell costimulatory 
molecules (in particular CPG and CD40L) by activating 
NF- ?B family proteins (Hon et al, 2004; Hou et al, 2004). 
Thus choosing a maturation signal, which can induce both 
maturation and increased life span of DCs may lead to 
effective T call response against tumor antigen. 
 
N. Dose, frequency and route of DC 
administration 
One of the most important limiting factors for the 
effective use of DC based vaccines is the ability of the 
injected DCs to reach secondary lymphoid organs to elicit 
T cell responses. Different studies have used different 
routes of delivery for immunotherapy. Intravenous, intra-
dermal, subcutaneous, intra-nodal, and intra-tumoral 
injections of DCs have been evaluated. Studies in humans 
indicate that intravenous injected DCs may preferentially 
localize to the lungs and afterwards, to spleen and liver 
(Mackensen et al, 1999). Conversely intra-dermal 
injection may result in DC migration to the afferent lymph 
nodes. A comparative study by Fong and colleagues, 2001 
suggests that Th1 immune response are more likely 
induced by intra-dermal injection than by other delivery 
methods. However, significant immune responses also 
have been noticed in studies that made use of 
subcutaneous and intravenous injections (Smith et al, 
1999). Route of administration may also directly affect the 
nature of T cell priming. Skin injections may be required 
to induce immunity to cutaneous tumors, whereas 
intravenous injections may be less effective at Th1 
induction but more effective at induction of humoral 
immunity. Injection into lymph nodes or lymphatics has 
also been attempted (Maier et al, 2003), to increase DC 
homing to lymphatics because only 5% or fewer DCs may 
migrate to draining nodes following subcutaneous 
injection. However, this mode of delivery often 
necessitates an ultrasonographic visualization of the lymph 
nodes to deliver the injection, and may lead to the damage 
of the lymph node. Direct injection of DC into tumors has 
also been investigated (Triozzi et al, 2000; Mazzolini et al, 
2005). The number of injected DCs into tumors may be 
equally important for induction of anti tumor response. 
High DC:T cell ratios polarize helper responses toward 
Th1 type in vitro and give rise to higher affinity T cells 
(Gett et al, 2003). In particular when DCs are pulsed with 
different peptides and injected separately into the skin, the 
number of DCs finally reaching the draining lymph node 
may simply to be too low to effectively induce T cell 
response. However in previous studies the number of 
injected DCs varied from 4 to 40 million cells per 
vaccination without striking differences being observed. 
The schedule and time duration of DC vaccination must be 
determined, as frequent T cell stimulation may lead to 
activation induced cell death, whereas activated cytotoxic 
T lymphocytes can kill antigen loaded dendritic cells that 
may diminish immune response (Ronchese et al, 2001). In 
fact, it is still unclear whether the anti- tumor immunity 
elicited by vaccination would last forever, in the absence 
of subsequent injections. These questions must be taken 
into account in the planning phase of DC based 
vaccination trials. 
 
O. Incorporating combinatorial strategies 
with DC therapy 
Although a number of the newer generation vaccines 
can effectively transfer antigen to and activate dendritic 
cells in vivo, T cell tolerance remains a major barrier that 
is difficult to overcome by therapeutic vaccinations. 
Preclinical models demonstrated that for poorly 
immunogenic tumors, therapeutic vaccine alone are 
ineffective at curing animals with a significant tumor 
burden, particularly once tolerance has been established. 
Combination of cancer vaccines administered in 
conjunction with inhibitors of immunologic checkpoints 
and agonists for Toll like receptors or T cell costimulatory 
pathway can overcome tolerance and generate significant 
anti-tumor immune responses even in cases of metastatic 
cancer. One of the most promising examples is the 
blockade of CTLA-4 inhibitory pathway (Leach et al 
1996). CTLA-4 binds to B7 at 10 fold higher affinity than 
does CD28 (Von Boehmer et al, 2005). Occupancy of 
CTLA-4 appears to directly counter the effect of CD28 on 
T cell activation and lymphokines induction (Lee et al, 
1998). Blockade of CTLA-4 has been shown to improve 
tumor immunosurveillence and amplify the effects of 
cancer vaccines in animals and recent clinical trial in 
melanomas (Hodi et al, 2003). However in vivo CTLA-4 
blockade predictably had effects beyond the antitumor 
response causing significant autoimmunity (Phan et al, 
2003). Although the vaccine and CTLA-4 combination 
approach induced autoimmune disease, the autoimmunity 
was confined to the tissue from which the tumor vaccine 
was derived (Van Elsas et al, 1999). Thus, the treatment of 
mice with B16 melanoma-GMCSF vaccine plus anti 
CTLA-4 antibody resulted exclusively in vitiligo–patchy 
de-pigmentation due to an auto immune response 
restricted to melanocytes, but no other signs of 
autoimmunity. These findings show that there is a 
hierarchy of tolerance induction, in which tolerance to 
tissue–specific antigens might be maintained by less 
stringently than tolerance to more–ubiquitous self-
antigens. Hsu and colleagues, 2002, have shown that 
CTLA-4 blockade maximizes anti tumor T cell activation 
by dendritic cells by presenting idiotype protein. These 
studies suggest that safe and effective disruption of 
checkpoint signals could yield substantial therapeutic 
benefit. The dissection of signaling pathways in T cells 
has revealed several additional potential targets for 
inhibitors of immunological checkpoints. The membrane 
molecule programmed cell death1 (PD1), expression of 
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which is induced after T cell activation, is a CTLA-4 like 
inhibitory molecule that decreases cytokine responses in T 
cells and might enhance their activation induced cell death 
(Zha et al, 2003). PD1 is a receptor for two of the newer 
B7 family members, B7-H1/PDL1 and B7-DC/PDL2 can 
co-stimulate enhanced cytokine production by naïve T 
cells, it is probable that PD1 is a counter–regulatory 
inhibitory receptor paired with an as yet unidentified 
costimulatory receptor on naïve T cells (Greenwald et al, 
2004). Dong and colleagues, 2002 reported that the B7-H1 
is expressed in many human cancers and promotes 
apoptotic death of activated tumor antigen specific T cells. 
Another study by Curiel and colleagues, 2003 suggest that 
B7-H1 expression is up regulated on myeloid DC (MDC) 
from tumor bearing patients, blockade of B7-H1 enhanced 
MDC mediated T cell activation and was accompanied by 
down regulation of T cell interleukin (IL)-I0 and up 
regulation of IL-2 and IFN-?.  
Regulatory T cells suppress T cell responses in both 
Antigen-specific and non-specific manner, in part through 
membrane bound TGF-? and IL-10 secretion and provide 
another mechanism for compromising the development of 
effective tumor immune response (Berencsi et al, 2002; 
Nishikama et al, 2005). Such cells are induced by 
antigens, especially in the absence of inflammatory 
signals, particularly in the presence of TGF-? and have 
been detected in increased frequency in some cancer 
patients (Ormandy et al, 2005). Thus depletion of Treg in 
vivo leads to effective anti tumor T cell response in murine 
models resulting in effective anti-tumor T cell responses 
(Shimizu et al, 1999). However activated effector CD8 
and CD4 Tcells also express CD25, depletion of these 
cells during acute phase of the anti-tumor T cell response 
may severely limit the application of this approach. Thus 
defining alternative molecules that permit selective 
targeting of Treg cells for depletion, such as GITR, should 
uncover greater anti tumor activity. In a ground breaking 
study by Peng and colleagues, 2005, suggested that 
activation of TLR signaling using ligand TLR8 can 
reverse the Treg cell function. This effect was independent 
of dendritic cells but required functional TLR8-MyD88-
IRAK4 signaling in Treg cells. Adoptive transfer of TLR8 
ligand stimulated Treg cells into tumor bearing mice 
enhanced anti-tumor immunity. These results suggest that 
TLR8 signaling could play a critical role in controlling 
immune responses to cancer. Although the development of 
immune based therapies for various cancers heralded with 
much hope and optimism objective clinical improvements 
in most vaccinated cancer patients have not been realized. 
To broaden the search for vaccine induced benefits, 
couples of investigators are being involved in studying the 
synergy of vaccines with conventional chemotherapy 
(Emens et al, 2005; Lake and Robinson, 2005). The 
approach of using combined chemotherapy and 
immunotherapy shown to induce better immunity resulted 
in complete eradication of tumors in mouse models. In a 
recent study by Wheeler and colleagues, 2005 examined 
the synergy of vaccines with conventional chemotherapy 
in patients with glioblastoma. Vaccinated patients 
receiving subsequent chemotherapy exhibited significantly 
longer times to tumor recurrence after chemotherapy 
relative to their own previous recurrence times, as well as 
significantly longer postchemotherapy recurrence times 
and survival to patients receiving isolated vaccination or 
chemotherapy. These data have significant implications 
for the development of new protocols combining 
chemotherapy with immunotherapy, indicating an exciting 
potential for therapeutic synergy with general applicability 
to many cancers. 
 
II. Conclusion 
Variables associated with employing dendritic cell 
vaccines for tumor immunotherapy are numerous (Figure 
6). To achieve effective anti-cancer immune response, we
 
 
 
Figure 6. Summary of the DC-based 
anti-cancer therapy. DCs can be 
generated from the PBMC 
progenitors using GM-CSF and IL-4. 
The resultant immature DCs can be 
used for loading with tumor 
antigens, which are then matured 
with suitable maturation signal and 
then re-infused back into the patient.
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must consider the use of the best lineage of dendritic cell 
for antigen delivery. These DC once identified, the next 
question is should we use DC directly isolated from the 
peripheral blood or generate them ex vivo from precursors 
or even better we should induce then in vivo? Next, how 
do we load the antigen? Maturation and/or activation are 
the other factors to consider, as data suggest immature 
dendritic cells may give a diminished immune response. 
Furthermore, the route of DC vaccine administration is 
always a question with tumor vaccines, as there are 
advantages and disadvantages to all of the available routes. 
Perhaps most importantly, we need to understand how best 
to evaluate the immune and clinical response to dendritic 
cell vaccines to permit efficient development of this 
strategy for effective immunotherapy against cancer. 
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